Category: About VRD

About VRD – Vrd.co

GSK announces positive headline results from the pivotal DREAMM-2 study for multiple myeloma

Issued: London UK GlaxoSmithKline plc (LSE/NYSE: GSK) today announced positive headline results from the pivotal DREAMM-2 open-label, randomised study of two doses of belantamab mafodotin (GSK2857916). The 196 patients in the trial had relapsed multiple myeloma, were refractory to an immunomodulatory drug, a proteasome inhibitor, and to treatment with an anti-CD38 antibody. The two-arm study met its primary objective and...

READ MORE GSK announces positive headline results from the pivotal DREAMM-2 study for multiple myeloma

DREAMM-2 and DREAMM-6 data at ASCO reinforce the potential of GSK’s investigational belantamab mafodotin in patients with relapsed/refractory multiple myeloma

For media and investors only Issued: London, UK EDITOR’S NOTE: This press release has been updated to reflect a median overall survival of 13.7 months instead of 14.9 months based on a re-analysis of the DREAMM-2 study following the identification of a discrepancy in patient data used to calculate overall survival estimates. (Updated as of 30/06/2020) 13-month update on the...

READ MORE DREAMM-2 and DREAMM-6 data at ASCO reinforce the potential of GSK’s investigational belantamab mafodotin in patients with relapsed/refractory multiple myeloma

Generated by Feedzy